Institut Català de la Salut
[Pujals M] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Resar L] Department of Medicine, Division of Hematology, The Johns Hopkins University School of Medicine, Baltimore, USA. Departments of Medicine (Hematology), Oncology, Pathology and Institute of Cellular Engineering, The Johns Hopkins University School of Medicine, Baltimore, USA. Pathobiology, Cellular and Molecular Medicine and Human Genetics Graduate Programs, The Johns Hopkins University School of Medicine, Baltimore, USA. [Villanueva J] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain
Vall d'Hebron Barcelona Hospital Campus
2022-06-16T06:39:54Z
2022-06-16T06:39:54Z
2021-09-09
HMGA1; Secretome; Unconventional protein secretion
HMGA1; Secretoma; Secreción de proteínas no convencionales
HMGA1; Secretoma; Secreció de proteïnes no convencionals
The gene encoding the High Mobility Group A1 (HMGA1) chromatin remodeling protein is upregulated in diverse cancers where high levels portend adverse clinical outcomes. Until recently, HMGA1 was assumed to be a nuclear protein exerting its role in cancer by transcriptionally modulating gene expression and downstream signaling pathways. However, the discovery of an extracellular HMGA1-RAGE autocrine loop in invasive triple-negative breast cancer (TNBC) cell lines implicates HMGA1 as a “moonlighting protein” with different functions depending upon cellular location. Here, we review the role of HMGA1, not only as a chromatin regulator in cancer and stem cells, but also as a potential secreted factor that drives tumor progression. Prior work found that HMGA1 is secreted from TNBC cell lines where it signals through the receptor for advanced glycation end products (RAGE) to foster phenotypes involved in tumor invasion and metastatic progression. Studies in primary TNBC tumors also suggest that HMGA1 secretion associates with distant metastasis in TNBC. Given the therapeutic potential to target extracellular proteins, further work to confirm this role in other contexts is warranted. Indeed, crosstalk between nuclear and secreted HMGA1 could change our understanding of tumor development and reveal novel therapeutic opportunities relevant to diverse human cancers overexpressing HMGA1.
This research was supported by a grant from Instituto de Salud Carlos III through the project “PI19/01292” (Co-funded by European Regional Development Fund/European Social Fund “A way to make Europe”/“Investing in your future”).
Article
Published version
English
Oncogens; Càncer; DISEASES::Neoplasms; CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::DNA-Binding Proteins::HMGA Proteins::HMGA1a Protein; Other subheadings::Other subheadings::Other subheadings::/metabolism; PHENOMENA AND PROCESSES::Genetic Phenomena::Genetic Structures::Genome::Genome Components::Genes::Genes, Neoplasm::Oncogenes; ENFERMEDADES::neoplasias; COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas de unión al ADN::proteínas HMGA::proteína HMGA1a; Otros calificadores::Otros calificadores::Otros calificadores::/metabolismo; FENÓMENOS Y PROCESOS::fenómenos genéticos::estructuras genéticas::genoma::componentes genómicos::genes::genes de neoplasias::oncogenes
MDPI
Biomolecules;11(9)
https://doi.org/10.3390/biom11091334
info:eu-repo/grantAgreement/ES/PE2017-2020/PI19%2F01292
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/